New trial
Window Trial of Fluorescently Labeled Panitumumab in Head and Neck Cancer
- Trial ID
- NCT06819228 on ClinicalTrials.gov
- Cancer type
- Head and Neck Cancer
- Published in
- New in Oncology - May 21, 2025
This trial at Vanderbilt is evaluating Panitumumab-IRDye800 in resectable HNSCC to optimize dosing and enhance tumor visualization during surgery. The study aims to refine the balance between effective cancer imaging and safety to improve surgical margin decisions.
More in head and neck cancer
-
Trial result · Oct 15, 2026 · NCT05323656
Setanaxib + pembrolizumab misses its tumor-shrinkage endpoint but shows exploratory survival signals in CAF-rich head and neck cancer -
Trial result · Oct 1, 2026 · NCT04260126
PDS0101 (HPV16-targeted immunotherapy) + pembrolizumab drives 34% ORR and 39.3-mo mOS in 1L HPV16+ R/M HNSCC -
New trial · Sep 24, 2026 · NCT07773987
Phase 2 pembrolizumab PD-1 inhibitor plus hypofractionated RT tests ENI nodal-sparing strategy -
New trial · Sep 24, 2026 · NCT07807163
Phase 2 ficerafusp alfa (BCA101) EGFR×TGF-β bifunctional antibody + pembrolizumab -
New trial · Sep 24, 2026 · NCT07796126
Phase 2 toripalimab PD-1 (CD279) antibody “priming” before paclitaxel microtubule inhibitor in HNSCC